Accession Number: | 0001169245-21-000061 |
Date: | 2021-06-03 |
Issuer: | PHASEBIO PHARMACEUTICALS INC (PHAS) |
Original Submission Date: |
LOEWY CAROLINE M
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN, PA 19355
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NON-EMPLOYEE DIRECTOR STOCK OPTION (RIGHT TO BUY) | 3.53 | 2021-06-03 | deemed execution date | A | 14,000 (a) | 2031-06-03 | common stock 14,000 | $3.53 | 14,000 | direct |
ID | footnote |
---|---|
f1 | the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date |